Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1756-6614

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer ; volume:16 ; number:1 ; day:1 ; month:3 ; year:2023 ; pages:1-11 ; date:12.2023
Thyroid research ; 16, Heft 1 (1.3.2023), 1-11, 12.2023

Creator: Lang, Matthias
Longerich, Thomas
Anamaterou, Chrysanthi

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13044-023-00147-7

URN: urn:nbn:de:101:1-2023041221072499716621

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:54 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Lang, Matthias
Longerich, Thomas
Anamaterou, Chrysanthi
SpringerLink (Online service)

Other Objects (12)

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

Related objects

Reset password